Armata's presentation is scheduled for
About
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Contact:
Tel: 310-665-2928
Email: ir@armatapharma.com
Investor Relations
Tel: 212-915-2569
Email: jallaire@lifesciadvisors.com
(C) 2024 Electronic News Publishing, source